Member Info for Celtic007

The chance of any bad data is close to zero, even the pessimists here would admit that. The question how good is the data package and the way forward regarding funding. Soon find out.

The chance of any bad data is close to zero, even the pessimists li

Hi Lazarus. I would be stunned if no one of the major pharmaceutical were not sniffing about to see the data. If not, can only mean four things. first we are asking for stupid cash upfront and forwarding payments if onlicencsed. Doubt this , as sareum have constantly put out the previous licence deals. Second is that data is rubbish, not going to happen. The third one, being made offers that are ridiculously low, but again unlikely. The fourth , a TO and arguing over price for the whole lot.

Lol .. HBD. Made me laugh. It's all about the data package. Sadoldgit expects us to kick ass in psoriasis and beat all them competitors with validated high scores , but ours once daily.

Exactly Damon and show off your data

...the big pharmaceuticals have been crying out that they want the tyk drugs

Funnyguy, you are like a relapsed drinker. Doing good good recently and now hit the bottle again. Come on stay off it, not funny guy.

A capsule and once daily dosing and great side effects profile

I think a lot of here , the real shareholders maybe don't understand the beauty of two closely linked molecules. This in itself causes anyone looking at taking us over to on licence to say but what if 1802? We are the only ones in the pharmaceutical world to have a tyk2 cancer molecule. Good be a stroke of genius, that these two geek scientists had thought about two diversions.

If data package is good, then majors will look at others molecules there. Think Stephen has mentioned previously about the importance of having both.

Surfie, hopefully we can both chuckle soon if you are a holder. This without news drifts up and down .. the unknowns need answering , data package and the way forward. I am positive as are a lot others here. Yesterday b was a very good good day of detailed analysis by some smart individuals.

Hi meg. You seemed offended at one of my posts last night. Don't know why and no reply back.

The chuckle brothers back ...a tag team bless.

Good spot Steve g. Interesting times

That looks very good and manageable, should it be that we need to go it alone. Remember sadoldgit, saying posirisis was the easiest indication to target.

Sorry meg, I don't understand. I mean a lot of holders probably don't understand the full potential that exists in having two similar molecules for two massive indications. Both inter linked, so really would you want one and leave the other.

Hope that clears it ...confused

Some brilliant posts today and has been a long time coming. We will be talking to a few and as said, no new tyk2 drugs will just on the shelf, unless pants and that is not going to happen.

I think a TO IS high probability, as if data package for 1801 is good then you pay a 500 million to 750 to take it all , especially 1802.

It makes sense. I think sareum having 1801 and1802 could be a masterstroke that a lot of us did not realise we had.

Potnak, known you a long time but by god of you think surfie posts are ok here, even if they are consistently posting diarrhoea.

You also potnak, are one minute posting that you be disappointed if don't get at least £8 a share and £2 billion valuation then you go negative again. I know you are trading there so good luck to you.

Your swingometer is also all over the place. But please don't tell me surfie posts are valid, just deramping and baseless , like others who know they are. Their history shows not anything positive about sareum.

Let's see what happens

Beautifully put sadoldgit.

Lets agree to disagree. Let's see. Have a nice day. Life is too short to fight here like kids .

I am not ramping surfie, IF the data package is good this should have attracts....I have not ramped .. very simple ...data package needs to be good and enticing .

You have no constructive view, all negative , nothing posters like your associates .

Which is why the logic if data package good for tyk2 autoimmune then take the risk and take the whole lot....£1billion up a major is small change ....they have to take a risk...not such thing as a certainty till further trials but if no movement to then others get in and price goes up exponentially.

Risk reward